Aytu BioPharma Inc. (AYTU)
NASDAQ: AYTU
· Real-Time Price · USD
1.33
-0.02 (-1.48%)
At close: May 01, 2025, 3:52 PM
-1.48% (1D)
Bid | 1.31 |
Market Cap | 8.21M |
Revenue (ttm) | 68.76M |
Net Income (ttm) | -5.25M |
EPS (ttm) | -2.08 |
PE Ratio (ttm) | -0.64 |
Forward PE | 0.99 |
Analyst | n/a |
Ask | 1.36 |
Volume | 70,100 |
Avg. Volume (20D) | 36,773 |
Open | 1.35 |
Previous Close | 1.35 |
Day's Range | 1.31 - 1.47 |
52-Week Range | 0.95 - 3.45 |
Beta | 0.07 |
About AYTU
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the...
Sector Healthcare
IPO Date Sep 25, 2008
Employees 102
Stock Exchange NASDAQ
Ticker Symbol AYTU
Website https://aytubio.com
2 months ago
-0.72%
Aytu BioPharma shares are trading higher after the...
Unlock content with
Pro Subscription
5 months ago
-11.43%
Aytu BioPharma shares are trading lower. The company reported Q1 financial results.

2 months ago · accessnewswire.com
Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial ResultsNet income of $0.8 million Adjusted EBITDA1 of $1.3 million Pediatric Portfolio net revenue up 86% sequentially First quarterly sequential prescription increase for both ADHD and Pediatric portfolios ...